Key Takeaway: On December 31, 2023, Sanofi reported its total number of voting rights and shares in compliance with French commercial regulations. The company revealed that it has issued 1,264,799,969 shares, resulting in 1,410,152,297 real voting rights and a theoretical total of 1,423,602,685 voting rights, including treasury shares. This information is part of Sanofi's regular regulatory disclosures and can be accessed on their official website. The disclosure reflects standard corporate governance practices to inform stakeholders about shareholding and voting dynamics.
Price reaction · baseline $51.56 (2024-01-16 close) · hit after-hours · clean, no other SNY news in the window
day 0 close
+0.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+11%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
teplizumab/mL
Phase 2 · Diabetes Mellitus, Type 1
Full Press Release Details
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
a French société anonyme with a registered share capital of 2,529,036,828 €
Registered office : 46, avenue de la Grande Armée - 75017 Paris - France
Registered at the Paris Commercial and Companies Registry under number 395 030 844
Date
Total number of issued shares
Number of real voting rights (excluding treasury shares)
Theoretical number of voting rights (including treasury shares)*
December 31, 2023
1,264,799,969
1,410,152,297
1,423,602,685
* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.
This information is also available on the internet website of sanofi under « Regulated Information in France »: